Trevi Therapeutics, Inc. (TRVI) Social Stream

Featured Post From StockTwits About TRVI

$TRVI This should not be sitting at this price.

$3B+ est. PN global category in
$20B pruritus market
PRISM: Ph2b/3 study of pruritus in
PN enrollment expected to be
completed in 2H 2021 with top-line
data 1H2022
• Fast Track designation granted for
moderate to severe pruritus in PN

$4B est. IPF global category in $10B
chronic cough market
CANAL: Ph2 study of chronic cough
in IPF has restarted enrollment
post-covid, with top-line data
expected 1H2022